|
2025
|
Invention
|
Benzene derivative.
A compound represented by general formula (I) (in the formula, all symbols a... |
|
|
Invention
|
Immunosuppresive agent.
The present application provides an immunosuppressive agent containing a... |
|
2024
|
G/S
|
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic ... |
|
|
Invention
|
Bicyclic compound and use thereof for medical purposes.
Since a compound represented by the gene... |
|
|
Invention
|
Method for preparing dihydronaphthalene derivative. An object of the present invention is to prov... |
|
|
Invention
|
Ep4 agonist. A compound represented by general formula (I) (wherein all symbols have the same mea... |
|
|
Invention
|
Dp antagonist.
An object of the present invention is to provide a DP receptor antagonist. A comp... |
|
|
Invention
|
Sting agonistic compound.
A drug or agent containing a compound having an agonistic activity to ... |
|
|
Invention
|
Eye drop containing sepetaprost. The purpose of the present invention is to provide a sepetaprost... |
|
|
G/S
|
Pharmaceutical preparations and other preparations for
destroying vermin fungicides herbicides; ... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical substances; anti-cancer preparations; chemical prepar... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical prepa... |
|
|
Invention
|
Hla/cancer antigen pvt1-derived peptide complex-specific antibody. The present invention addresse... |
|
|
Invention
|
Inspection system, inspection method, and program. Provided are an inspection system, an inspecti... |
|
|
Invention
|
Compounds having s1p5 receptor agonistic activity.
A compound represented by the general formula... |
|
|
Invention
|
+ channels) channel function. Disclosed is a compound of formula (I), wherein all symbols are def... |
|
|
Invention
|
Bispecific antibody.
A bispecific antibody which is capable of specifically binding to PD-1 and ... |
|
|
Invention
|
Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies. Collapsin Response M... |
|
|
Invention
|
Substituted cyclopenta[c]pyrroles as abhd6 antagonists.
A drug is provided, which contains, as a... |
|
|
Invention
|
Antibody preparation. The problem addressed by the present invention is to provide a novel prepar... |
|
|
Invention
|
Tricyclic compound. To provide a compound having EP3 agonist activity. A compound represented by ... |
|
|
Invention
|
Prophylactic and/or therapeutic agent for kidney diseases containing tricyclic compound. Provided... |
|
|
Invention
|
Gba1 and gcs dual modulator. A compound represented by formula (I) or a pharmaceutically acceptab... |
|
2023
|
Invention
|
Purinone derivative hydrochloride.
The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrr... |
|
|
Invention
|
Composition for increasing sperm count and/or sperm concentration. Provided is a composition for ... |
|
|
Invention
|
Therapeutic agent for solid cancers, which comprises axl inhibitor as active ingredient.
A thera... |
|
|
Invention
|
Information processing device, program, and information processing method. [Problem] To provide a... |
|
|
Invention
|
Abhd6 antagonist. The purpose of the present invention is to provide a drug for the prevention an... |
|
|
Invention
|
Substituted cyclopenta[c]pyrroles as abhd6 antagonists. A drug is provided, which containing, as ... |
|
|
Invention
|
Compound having inhibitory activity against diacylglycerol kinase α and/or ζ, and pharmaceutical ... |
|
|
Invention
|
Bispecific antibody. The present invention addresses the problem of providing a novel drug for pr... |
|
|
Invention
|
Her2 targeting agent. An antibody or antigen-binding fragment thereof is disclosed. The antibody ... |
|
|
Invention
|
Purinone derivative.
Compounds represented by general formula (I) (all of the symbols in the for... |
|
|
Invention
|
Chimeric antigen receptor for tumor targeting. Provided are chimeric antigen receptors (CAR) spec... |
|
|
Invention
|
Sting agonistic compound. A drug or agent containing a compound having an agonistic activity to S... |
|
|
Invention
|
Single nucleotide polymorphism haplotype analysis method in human sting1 gene. The problem addres... |
|
|
Invention
|
Compound having kdm5 inhibitory activity and pharmaceutical use thereof. Disclosed are compounds ... |
|
|
G/S
|
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for ... |
|
|
Invention
|
Composition for ophthalmic use containing sepetaprost. The purpose of the present invention is to... |
|
|
G/S
|
Chemicals for use in the manufacture of pharmaceuticals;
chemicals for use in the manufacture of... |
|
|
Invention
|
Immunity enhancing agent for cancer by allergin-1 antagonist.
A method for suppression of progre... |
|
|
Invention
|
Novel compound, a-synuclein aggregate binder, and use thereof.
Provided is a compound that has h... |
|
|
Invention
|
Novel compound, α-synuclein aggregate binder, and use thereof. Provided is a compound that has hi... |
|
|
Invention
|
Monoclonal antibodies to programmed death 1 (pd-1).
The present invention provides isolated mono... |
|
|
Invention
|
Cancer treatment agent including malt1 inhibiting drug as active ingredient. The combination of a... |
|
|
Invention
|
Hmgn partial peptide and cancer therapy using the same. Disclosed are a novel therapeutic means e... |
|
2022
|
Invention
|
Agent for suppressing post-surgical cancer recurrence and/or metastasis.
A suppression of postsu... |
|
|
Invention
|
Process for making an ep4 antagonist.
The present disclosure provides the methods for making 4-[... |
|
|
Invention
|
Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitor... |
|
2021
|
Invention
|
Her2 targeting agent.
An antibody that binds to HER2 expressed on a cancer cell or a fragment of... |
|
|
Invention
|
Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor.
The object of... |
|
|
Invention
|
Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis.
A prophylactic and/or t... |
|
|
Invention
|
Novel compound, a-synuclein aggregate binder, and use thereof.
An embodiment of the present inve... |
|
2020
|
Invention
|
Inhibitors of trek (twik related k+ channels) channel function.
Disclosed is a compound of formu... |
|
|
Invention
|
Modulators of trek (twik related k+ channels) channel function.
Disclosed is a compound of formu... |
|
|
G/S
|
venture capital financing; venture capital fund management; venture capital advisory services; pr... |
|
2018
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for the treatment of liver, digestive, r... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical pre... |
|
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
Anti-infectives; anti-inflammatories; antibacterial
pharmaceuticals; antibiotics; antifungal pre... |
|
2017
|
G/S
|
Organizing, arranging and conduction of educational seminars; educational services. Testing, insp... |
|
2015
|
G/S
|
Pharmaceuticals. Printed publication; pamphlets in the field of medical
science and medication; ... |
|
2004
|
G/S
|
Medical research for all pharmaceuticals and medicines Medical testing services |
